University of Debrecen
Welcome,         Profile    Billing    Logout  
 8 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Illes, Arpad
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruiting
3
117
Europe, RoW
Ropeginterferon alfa-2b (BESREMi®)
AOP Orphan Pharmaceuticals AG
Essential Thrombocythaemia
03/28
03/28
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
Fülesdi, Béla
NCT06517524: Effects of Low-pressure Pneumoperitoneum Associated With Deep Pipecuronium-induced Neuromuscular Blockade on Hemodynamic Parameters for High Cardiovascular Risk Patient Undergoing General Anesthesia

Completed
N/A
10
Europe
Tamas Vegh, MD
Residual Neuromuscular Block, Cardiovascular Diseases, Neuromuscular Blockade Monitoring
06/24
06/24
NCT06691204: Comparison of Adductor Pollicis and Abductor Digiti Minimi Muscles (Thumb Vs. Fifth Digit) As Sites for Neuromuscular Monitoring with Electromyography

Recruiting
N/A
46
Europe
Tamas Vegh, MD
Postoperative Residual Curarization, Neuromuscular Blockade
05/26
05/26
NCT06754995: Diagnostic Feasibility of 100 Hz Tetanic Stimulation

Not yet recruiting
N/A
40
Europe
University of Debrecen
Polyneuropathies
12/26
12/27
Nagy, Gergely G
DONATE, NCT05709184: Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection

Recruiting
N/A
196
Europe, Canada, RoW
Lyophilized fecal microbiome transfer, FMT, Vancomycin, CDI antibiotic treatment
Rambam Health Care Campus, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, European Institute of Oncology, University of Alberta, Imperial College London, University of Debrecen, Lithuanian University of Health Sciences
Clostridioides Difficile Infection
11/25
03/26
Papp, Maria
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
NCT05056220: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Recruiting
3
240
Europe
Human albumin, sodium chloride
Aleksander Krag, EASL - CLIF Consortium
Decompensated Cirrhosis and Ascites
03/25
04/25
GLOBAL-AKI, NCT05387811: International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Completed
N/A
1456
Europe, US, RoW
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Azienda Ospedaliera di Padova
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
09/23
11/23
Tibor, Szűk
Morpheus, NCT02901353: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry

Recruiting
N/A
400
Europe, RoW
Sirolimus Eluting Coronary Stent System
Meril Life Sciences Pvt. Ltd.
Angina Pectoris
12/20
12/22
Pall, Denes
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
Kolozsi, Péter
TOPO, NCT05238584: Total Versus Partial Omentectomy in the Treatment of Gastric Cancer

Recruiting
N/A
300
Europe
Partial omentectomy
University of Debrecen, National Institute of Oncology, Hungary, University of Pecs, Uzsoki Street Hospital, Hungary
Stomach Neoplasms, Interleukin, Stomach Cancer, Gastric Cancer, Digestive System Neoplasm
12/23
07/24
Surgi-Comics, NCT05779254: SURGIcal COmplication and MIcrobiome ChangeS in Colorectal Surgery

Recruiting
N/A
100
Europe
Neomycin Sulfate, Metronidazole
Uzsoki Hospital, University of Debrecen, Csolnoky Ferenc Hospital
Anastomotic Leak, Microbial Colonization
01/25
01/26
Remenyik, Judit
NCT05406011: Effect of Sour Cherry Anthocyanins on Healthy Human Saliva

Enrolling by invitation
N/A
20
Europe
Pelleted sour cherry (anthocyanin) containing chewing gum usage., Pelleted chewing gum for stimulated saliva sampling., Scaling
University of Debrecen
Dental Caries
08/23
12/24
Bágyi, Kinga
NCT05406011: Effect of Sour Cherry Anthocyanins on Healthy Human Saliva

Enrolling by invitation
N/A
20
Europe
Pelleted sour cherry (anthocyanin) containing chewing gum usage., Pelleted chewing gum for stimulated saliva sampling., Scaling
University of Debrecen
Dental Caries
08/23
12/24
Kovács, Tamás
CHOICE, NCT05445349: Breathing Parameter Measurements for Lung Deposition Simulation

Active, not recruiting
N/A
163
Europe
Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
Medisol Development Kft., Pest County Pulmonology Hospital, University of Debrecen, St. Borbala Hospital, Medical Centre Hungarian Defence Forces, Hospital of Komló, St. Pantaleon Hospital in Dunaújváros
Asthma, COPD
06/24
06/25
Vaskó, Attila
CHOICE, NCT05445349: Breathing Parameter Measurements for Lung Deposition Simulation

Active, not recruiting
N/A
163
Europe
Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
Medisol Development Kft., Pest County Pulmonology Hospital, University of Debrecen, St. Borbala Hospital, Medical Centre Hungarian Defence Forces, Hospital of Komló, St. Pantaleon Hospital in Dunaújváros
Asthma, COPD
06/24
06/25
Bay, Peter
Surgi-Comics, NCT05779254: SURGIcal COmplication and MIcrobiome ChangeS in Colorectal Surgery

Recruiting
N/A
100
Europe
Neomycin Sulfate, Metronidazole
Uzsoki Hospital, University of Debrecen, Csolnoky Ferenc Hospital
Anastomotic Leak, Microbial Colonization
01/25
01/26
Svanadze, Zviad
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
Szük, Tibor
CTO-DENOVO, NCT05977842: Drug-coated Balloon in de Novo Chronic Total Occlusions

Recruiting
N/A
250
Europe, RoW
CTO PCI using DCB-only strategy
National Institute of Cardiology, Warsaw, Poland
Coronary Artery Disease, Total Occlusion of Coronary Artery
02/25
03/25
Asztalos, László
NCT06544980: Measuring Upper Airway Cross Sectional Areas During Residual Neuromuscular Blockade and After Reserval

Recruiting
N/A
20
Europe
Tamas Vegh, MD
Postoperative Residual Curarization, Airway Obstruction on Anaesthetic Emergence
12/25
12/25
NCT06754995: Diagnostic Feasibility of 100 Hz Tetanic Stimulation

Not yet recruiting
N/A
40
Europe
University of Debrecen
Polyneuropathies
12/26
12/27

Download Options